The provision of a live attenuated intranasal influenza vaccine. The vaccine will be used to support the extension to the annual seasonal influenza vaccination programme, that extension being to include children. Deliveries will be required over a period of 3 years beginning in the 2014 influenza season, with an option to extend for a further year.